This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy Study of Iferanserin to Treat Hemorrhoids

This study has been completed.
Information provided by (Responsible Party):
Ventrus Biosciences, Inc Identifier:
First received: November 22, 2011
Last updated: August 19, 2013
Last verified: November 2011
To evaluate the safety and efficacy of topical 0.5% S-MPEC cream vs. placebo cream (applied twice daily for 14 days) in the treatment of Grade I - III hemorrhoids.

Condition Intervention Phase
Hemorrhoids Drug: Iferanserin Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Protocol for the Study of the Effects of S-MPEC (Iferanserin) in Patients With Hemorrhoids

Resource links provided by NLM:

Further study details as provided by Ventrus Biosciences, Inc:

Primary Outcome Measures:
  • Assessment of hemorrhoid bleeding [ Time Frame: Day 7 and 14 ]
    Change from pre-treatment in patient assessment of hemorrhoid bleeding (10-point scale: 1=Not at all, 10=Extremely) at the end of one- and two-weeks of treatment are the primary efficacy endpoints for the study.

Secondary Outcome Measures:
  • Assessment of bleeding, hemorrhoid size, other hemorrhoid symptoms, and physician evaluation of hemorrhoids. [ Time Frame: 14 days ]
    Change from pre-treatment in patient assessment of bleeding on other treatment days, change from pre-treatment in hemorrhoid size, change from pre-treatment in patient assessment of other hemorrhoid symptoms/conditions on all treatment days, and physician evaluation of hemorrhoids at the end of treatment.

Enrollment: 121
Study Start Date: September 2001
Study Completion Date: August 2002
Primary Completion Date: August 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Iferanserin
Iferanserin administration intra-anally twice daily for 14 days
Drug: Iferanserin
Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
Other Name: VEN309
Placebo Comparator: Placebo
Placebo administration intra-anally twice daily for 14 days
Drug: Placebo
Placebo ointment applied intra-anally twice daily for 14 days


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Diagnosis of grade I - III hemorrhoids with bleeding episodes of at least every other day during the last two weeks before enrollment in the study.
  • Patients signing the Informed Consent form.

Exclusion Criteria:

  • Patients with protruding or irreducible hemorrhoids (grade IV).
  • Patients with anal fistulas, periproctitis or hemorrhagic diathesis
  • Patients with current history of Type I or Type II diabetes mellitus.
  • Patients with severe hepatic, renal or cardiovascular disorders.
  • Patients with any type of infectious disease.
  • Patients who have been involved with another experimental drug trial within the past 30 days.
  • Patients presently diagnosed with cancer.
  • Patients who have known alcohol and drug abuse.
  • Patients who require the use of suppositories.
  • Patients with blood or urine laboratory values outside the normal limits or those with values considered abnormal in the opinion of the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01483833

Prof. Alexander Herold, MD
Mannheim, Germany
Sponsors and Collaborators
Ventrus Biosciences, Inc
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Ventrus Biosciences, Inc Identifier: NCT01483833     History of Changes
Other Study ID Numbers: VEN309-SMPEC-001
Study First Received: November 22, 2011
Last Updated: August 19, 2013

Additional relevant MeSH terms:
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on September 19, 2017